Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis

Gaebe, Karolina; Erickson, Anders W.; Li, Alyssa Y.; Youssef, Andrew N.; Sharma, Bhagyashree; Chan, Kelvin K.W.; Lok, Benjamin H.; Das, Sunit

doi:10.1016/j.eclinm.2023.102396

Cited by 6 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PCI group also reported a prolonged overall survival (OS) with an HR of 0.81 (p < 0.001). Another meta-analysis of 63 studies [38] corroborated this finding in 8906 patients with SCLC who received PCI, reporting a 55% risk-reduction in developing new BM with a relative risk (RR) of 0.45 (p < 0.001). Of those, 5470 patients with limited SCLC reported an RR of 0.45 (p < 0.0001) and 1763 patients with extensive disease reported an RR of 0.51 (p = 0.01).…”

Section: Prophylactic Cranial Irradiation In Sclcmentioning

confidence: 84%

Prevention of Brain Metastases: A New Frontier

Pellerino,

Davidson,

Bellur

et al. 2024

Cancers

View full text Add to dashboard Cite

This review discusses the topic of prevention of brain metastases from the most frequent solid tumor types, i.e., lung cancer, breast cancer and melanoma. Within each tumor type, the risk of brain metastasis is related to disease status and molecular subtype (i.e., EGFR-mutant non-small cell lung cancer, HER2-positive and triple-negative breast cancer, BRAF and NRAF-mutant melanoma). Prophylactic cranial irradiation is the standard of care in patients in small cell lung cancer responsive to chemotherapy but at the price of late neurocognitive decline. More recently, several molecular agents with the capability to target molecular alterations driving tumor growth have proven as effective in the prevention of secondary relapse into the brain in clinical trials. This is the case for EGFR-mutant or ALK-rearranged non-small cell lung cancer inhibitors, tucatinib and trastuzumab–deruxtecan for HER2-positive breast cancer and BRAF inhibitors for melanoma. The need for screening with an MRI in asymptomatic patients at risk of brain metastases is emphasized.

show abstract

Section: Prophylactic Cranial Irradiation In Sclcmentioning

confidence: 84%